9 terminated. 9 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 9 | Terminated 9 |
| Phase 3 | 1 | Terminated 1 |
Follow Impulsive Behavior: new trials by email Literature Review of Impulsive Behavior trials Research Report on Impulsive Behavior
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Guanfacine for Hyperactivity in Children With Down Syndrome (HYPEbeGONE_DS) Guanfacine Hydrochloride Immediate Release, Placebo - Hyperactivity in Children With Down Syndrome, Impulsivity in Children With Down Syndrome | Phase 2 | Terminated | Rachel G. Greenberg, MD, MB, MHS | 3 | 2024-12-09 | 2026-04-17 |
| Atomoxetine in Patients With Tourette's Syndrome Atomoxetine - Tourette Syndrome | Phase 2 | Terminated | Poitiers University Hospital | 5 | 2022-05-31 | 2024-01-23 |
| Oral Naltrexone In Pediatric Eating Disorders Naltrexone Hydrochloride, Control - Anorexia Nervosa/Bulimia, Anorexia in Adolescence | Phase 2 / Phase 3 | Terminated | Rosemary Claire Roden | 9 | 2022-04-22 | 2025-08-19 |
| Biased Opioid Agonists for Treatment of Opioid Withdrawal in OUD Placebo, TRV734, Oxycodone - Opioid-Use Disorder | Phase 2 | Terminated | National Institute on Drug Abuse (NIDA) | 5 | 2021-12-27 | 2026-06-02 |
| High Dose Bupropion for Smoking Cessation - Pilot Study Bupropion Hydrochloride - Smoking Cessation, Smoking, Tobacco | Phase 2 | Terminated | University of Southern California | 12 | 2021-09-01 | 2023-07-17 |
| A Study of Pleiotropic Pioglitazone Effects on the Alcoholic Lung (APPEAL Study) Pioglitazone - Alcoholism | Phase 2 | Terminated | Emory University | 50 | 2018-01-03 | 2023-02-14 |
| Establishment of Cessation Therapy by Clinical Trials for Subjects With Betel-quid Dependence and Oral Pre-cancer escitalopram, Moclobemide, Placebo - Cap - Addiction | Phase 2 | Terminated | China Medical University Hospital | 90 | 2016-01-14 | 2019-07-24 |
| Study to Evaluate the Effect of AFQ056 in Obsessive Compulsive Disorder (OCD) Patients Resistant to Selective Serotonin Reuptake Inhibitor (SSRI) Therapy AFQ056, Placebo - Patient Diagnosed With OCD and Resistant to SSRI Treatment, Failed SSRI Over 12 Weeks at Appropriate Doses | Phase 2 | Terminated | Novartis Pharmaceuticals | 50 | 2013-11-01 | 2017-01-02 |
| Safety and Efficacy Study of Vigabatrin to Treat Methamphetamine Dependence CPP-109 vigabatrin, Matching Placebo - Methamphetamine Dependence | Phase 2 | Terminated | Catalyst Pharmaceuticals, Inc. | 55 | 2008-07-01 | 2020-12-09 |
Behavior, Addictive (4) · Compulsive Behavior (2) · Alcoholism (1) · Anorexia Nervosa (1) · Bulimia (1) · Bulimia Nervosa (1) · Cigarette Smoking (1) · Feeding and Eating Disorders (1) · Obsessive Behavior (1) · Obsessive-Compulsive Disorder (1) · Opioid-Related Disorders (1) · Smoking (1) · Smoking Cessation (1) · Spasm (1)
Behavior (9) · Mental Disorders (5) · Compulsive Behavior (4) · Chemically-Induced Disorders (2) · Nervous System Diseases (2) · Pathological Conditions, Signs and Symptoms (2) · Signs and Symptoms (2) · Alcohol-Related Disorders (1) · Anxiety Disorders (1) · Basal Ganglia Diseases (1) · Behavioral Symptoms (1) · Brain Diseases (1) · Central Nervous System Diseases (1) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1)
Atomoxetine Hydrochloride (1) · Bupropion (1) · Escitalopram (1) · Guanfacine (1) · Moclobemide (1) · Naltrexone (1) · Oxycodone (1) · Pioglitazone (1) · Vigabatrin (1) · bisaramil (1) · mavoglurant (1)
Catalyst Pharmaceuticals, Inc. (1) · China Medical University Hospital (1) · Emory University (1) · National Institute on Drug Abuse (NIDA) (1) · Novartis Pharmaceuticals (1) · Poitiers University Hospital (1) · Rachel G. Greenberg, MD, MB, MHS (1) · Rosemary Claire Roden (1) · University of Southern California (1)
United States (7) · Bulgaria (1) · Czechia (1) · France (1) · Germany (1) · Switzerland (1)
Adam M Leventhal, PhD (1) · Charles W Gorodetzky, MD, PhD (1) · David Guidot, MD (1) · David H Epstein, Ph.D. (1) · Ko Ying-Chin, PHD (1) · Rachel Greenberg (1) · Rosemary C Roden, MD (1)
2019 (1), R01AA025857 (1)